IL-9 Governs Allergen-induced Mast Cell Numbers in the Lung and Chronic Remodeling of the Airways
Jennifer Kearley(AstraZeneca (Finland)), Alison A. Humbles(Institute of Neuroimmunology of the Slovak Academy of Sciences), Anthony J. Coyle(Immune Regulation (United Kingdom)), Carla P. Jones(Lung Institute), Leif Bjermer(Lund University), Jonas S. Erjefält(Lund University), Annette Robichaud(The Quebec Population Health Research Network), Yambasu A. Brewah(Institute of Neuroimmunology of the Slovak Academy of Sciences), Cecilia Andersson(Lund University), Timothy Burwell(Institute of Neuroimmunology of the Slovak Academy of Sciences), Clare M. Lloyd(Imperial College London), Ebony Benjamin(Institute of Neuroimmunology of the Slovak Academy of Sciences), Roland Kolbeck(AstraZeneca (Australia)), Peter A. Kiener(Institute of Neuroimmunology of the Slovak Academy of Sciences), Sophie Pégorier(Inserm)
American Journal of Respiratory and Critical Care Medicine
October 22, 2010
Cited by 211
Related Papers
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4 <b>+</b> CD25 <b>+</b> regulatory T cells is interleukin 10 dependent
|The Journal of Experimental Medicine|2005|515
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
|CHEST Journal|2016|426
EUFOREA consensus on biologics for CRSwNP with or without asthma
|Allergy|2019|378
Benralizumab for the Prevention of COPD Exacerbations
|New England Journal of Medicine|2019|329